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Purpose: This investigation explored factors associated with premenstrual syndrome (PMS)
in minority women, and compared the response of minority and non-minority women
supplemented with omega-3 fatty acids (FA) in the form of fish oil.
Methods: This descriptive, correlational, retrospective pilot was a secondary data analysis.
Participants consuming 2 g of fish oil/d (n ¼ 15) in the larger study were included. The
Moos Menstrual Distress Questionnaire (MMDQ) was assessed monthly for two months to
acquire a mean baseline MMDQ score. The total sample was stratified to evaluate
racial variations in PMS symptoms (non-minority, n ¼ 7; minority, n ¼ 8). MMDQ score at
5 months was compared to the mean baseline score within each group.
Results: Fish oil supplementation significantly reduced PMS symptoms in both groups (non-
minority p ¼ 0.002; minority p ¼ 0.046) with a large effect of 1.4 for both groups. Mean
MMDQ total scores were not significantly different between groups at 5 months.
Conclusions: This pilot evidence of improved PMS symptoms in minority and non-minority
groups related to fish oil supplementation supports a universal treatment approach and
highlights need for a larger-scale investigation.
Copyright © 2015, Chinese Nursing Association. Production and hosting by Elsevier
(Singapore) Pte Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Premenstrual syndrome (PMS) is a significant health issue
for women with a reported prevalence of 47.8% [1]. Premen-
strual syndrome can negatively impact a women's life for
up to six days monthly. Common symptoms of PMS include,
but are not limited to: depression, mood lability, abdominalu (M. Judge).
Nursing Association.
Association. Production
://creativecommons.org/pain, breast tenderness, headache and fatigue [2]. PMS is
associated with increased sick days, impaired work produc-
tivity, impaired marital relationships and homemaking diffi-
culties, and impaired functioning [3]. Reduced quality of life
has been reported in collegiate women suffering from PMS
with decreased educational productivity, disruptions in social
activities, and impairments in family relations [4]. Althoughand hosting by Elsevier (Singapore) Pte Ltd. This is an open access
licenses/by-nc-nd/4.0/).
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can be disruptive, the Diagnostic and Statistical Manual of
Mental Disorders (DSM-5) does not include PMS as an official
diagnosis [5].
Evidence is limited regarding differences in PMS symp-
tomatology between minority and non-minority populations.
Harlow et al. reported that although European-American
women had longer bleeds, African-American women had
heavier bleeding episodes compared to European-American
women [6]. Additionally, high perceived stress was associ-
ated with a 50% increase in heavy bleeding with African
American women having significantly higher levels of both.
Lastly, African American women have been reported to have
an earlier onset of menarche and menopause [6]. Ethnic dif-
ferences in bleeding duration, volume, perceived stress, and
age of menarche provide compelling evidence pointing to
differences in uterine and ovarian function, essential to un-
derstanding PMS.
Omega-3 fatty acids (FA) offer a promising alternative
intervention for alleviating PMS symptoms. Earlier work re-
ported significant correlations have been reported between
omega-3 FA supplementation and symptoms of aggression
[7], depression [8,9], concentration, and inflammatory disor-
ders [10,11]. Omega-3 supplementation has been reported
to improve cognitive performance in healthy subjects [12].
Although the literature is limited regarding the efficacy of
omega-3 fatty acids in alleviating PMS symptoms, existing
evidence supports this relationship [13,14].
Omega-3 FA's regulate neural membrane conduction
and can alter the brain's neurochemical profile including se-
rotonin, dopamine, GABA, and acetylcholine [15]. Enhanced
neurotransmission offers a plausible explanation for mood
elevation [8,9], a primary symptom of PMS. Inflammationmay
also be mitigated by omega-3 FA [10,11].
Very few investigations have evaluated the complex
array of lifestyle and other factors likely to influence PMS
severity. Factors including stress [16,17], exercise habits
[17,18], sleep quality [19], caffeine intake [17] and body mass
index (BMI) [17,20] have been evaluated previously related
to PMS symptomatology and evidence is largely inconclusive
to date. Further, factors including credit load, work in addition
to coursework, living situation and marital status are likely
to contribute to perceived stress level in collegiate women
however, these factors remain unexplored. Further research is
necessary exploring the influence of various factors on PMS
symptom severity and expanding the current literature. Un-
derstanding the influence of various factors on PMS symptom
severity is highly important for the development of inter-
vention strategies in women suffering from PMS.Fig. 1 e Supplementation timeline: Baseline monitoringGiven that PMS symptomatology includes depression,
difficulty concentrating, emotional lability, abdominal and
breast pain, headache and fatigue, omega-3 FA may offer a
promising alternative intervention in alleviating mood
and inflammatory disturbances [5e10]. This investigation
aimed to explore factors impacting PMS symptomatology in
minority women, and compare the response of minority
women to supplementation with omega-3 FA with a non-
minority cohort.2. Materials and methods
This descriptive correlational retrospective pilot was a sec-
ondary data analysis of data from a previous double blind
placebo controlled study. The focus of this analysis was to
explore factors associated with PMS in minority women, and
compare the response of minority and non-minority women
to supplementation with omega-3 FA. All participants in the
secondary analysis (n ¼ 15) consumed 2 g of fish oil daily for
3 months following the protocol of the original investigation
(Fig. 1.)
In the original investigation, there was and intervention
group (omega-3) and a placebo group. The intervention
group was given omega-3 fatty acid as 2 g fish oil, while the
placebo was given 2 g of wheat germ oil. The groups were
randomized using a computerized randomization program
and a master's level nursing student who is in no way associ-
atedwith the studyprepared thepackages for eachparticipant.
Packets contained a three month supply of capsules and each
packet was identical without information that would identify
capsule type and group assignment. Study numbers were
marked on the exterior of each packet contained information
regarding capsule storage, initiation and intake recording.
2.1. Participants
Recruitment was conducted in accordance with the IRB at the
University of Connecticut. Participants were collegiate female
women age 18e25. Once consented, a medical history form
was completed by those interested in participating in the
investigation. The medical history form was a self-report of
menstrual, medical, social history and demographic infor-
mation. Participants were deemed eligible if theymet the PMS
symptomatology profile and not the exclusionary criterion.
The exclusionary criterion included: diabetes, hypercholes-
terolemia, hyperlipidemia, hypertension, anticoagulants (ex:
low dose aspirin, Warfarin, Coumadin), renal or liver disease,
pregnant or planning on becoming pregnant, diagnosed withfor 2 months with supplementation at months 3e5.
Table 1 e Demographic characteristics at baseline
by group.
Minority
(n ¼ 8)
Mean (SD)
Non-minority
(n ¼ 7)
Mean (SD)
Body mass index (BMI) 22.87 (2.80) 23.03 (3.20)
Credit load 16.38 (2.07) 16.29 (2.56)
Hours worked
(per week)
7.25 (5.63) 6.43 (8.88)
Physical activity
(hrs. per week)
5.13 (3.09) 3.64 (2.75)
Caffeine intake
(caffeine drinks per day)
0.38 (0.52) 1.00 (1.41)
Daily sleep (hrs.) 6.56 (0.82) 7.36 (0.75)
Marital status 8 (single) 7 (single)
Living arrangement
1 ¼ On campus
2 ¼ Off campus
1 ¼ 7
2 ¼ 1
1 ¼ 6
2 ¼ 1
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drome, or currently being treated for depression/psychiatric
illness.
2.2. Study procedures
Packets were distributed containing the following items: i.)
3 month supply of capsules as outlined above; ii.) The Moos
Menstrual Distress Questionnaires (MMDQ) for 5 consecutive
months; iii.) The Capsule Supplementation Log. Baseline
PMS MMDQ assessments were conducted during the first 2
months of study participation. Following the second month,
capsules were initiated and consumed for a 3 month period.
During this 3 month period, MMDQ assessments and capsules
logs were recorded monthly. Participants were provided cal-
endars noting specific dates to initiate capsules and record
MMDQ responses. Participants were also contacted periodi-
cally by study personnel to ensure protocol compliance and
assess for adverse events.
2.2.1. Medical health history form
An initial medical history was obtained from participants to
ensure that they met study criteria. The exclusionary criteria
included, diabetes, hypercholesterolemia, hyperlipidemia,
hypertension, anticoagulants, renal or liver disease, pregnant
or planning on becoming pregnant, those diagnosed with pre-
menstrual dysphoric disorder or polycystic ovarian syndrome,
vegetarians, or those being treated for depression or psychi-
atric illnesses; all of which could potentially impact study
outcomes. Participants also indicated their daily caffeine
intake, hours slept each night, hours spent at work, credits
taken throughout the semester and additional medications or
nutritional supplements taken. These factorswereused to gain
a baseline of participant's overall stress levels and to evaluate
whether or not these affected their PMS symptoms or severity.
2.2.2. Moos menstrual distress questionnaire (MMDQ)
As previously mentioned, all participants completed the
Moos Menstrual Distress Questionnaires (MMDQ) monthly
throughout the five months of the study; the first 2 MMDQ
assessments were completed prior to the start of the inter-
vention to establish baseline PMS symptomatology and three
times during the three month intervention. The MMDQ is a
validated instrument that evaluates systematic and empirical
PMS symptoms [21]. Internal consistencies for the subscale
range from 0.92 to 0.64 [22]. This 46 item scale utilizes a Likert
scale of 0 (no symptoms experienced) to 4 (present, severe)
for Premenstrual, Menstrual, and Post-Menstrual phase. The
scale is divided into 8 domains: pain, water retentions, auto-
nomic reactions, negative affect, impaired concentration,
behavior changes, arousal, and control (score range is 0e192).
Baseline MMDQ scores from the original investigation (Fig. 1,
months 1 and 2) were averaged to obtain a baseline MMDQ
score. To assess PMS symptom response, differences between
baselineMMDQ score andMMDQ score at 5months (following
a 3-month period of supplementation) were compared.
2.2.3. Statistical analyses
Using SPSS version 20, paired t-tests were used to evaluate
within-group differences for both cohorts (minority andnon-minority). To explore group differences, PMS scores at 5
months were compared between non-minority and minority
women using an independent t-test. To explore factors asso-
ciated with PMS in minority women factors related to PMS
symptoms were correlated for the minority group using
Pearson's r correlation.3. Results
Baseline demographic characteristics including body mass
index (BMI), credit load, time spent working, physical activity,
consumption of beverages containing caffeine, daily sleep,
marital status and living situation are presented by group in
Table 1.
There was no group difference in PMS symptomatology.
A significant within group difference was found for both the
minority and non-minority between baseline MMDQ scores
and month 5 (Table 2), with a large effect size of 1.4 for both
the minority and non-minority women.
Significant negative correlations were found between
caffeine andMMDQ total score in minority women at baseline
and months 3 and 4, r (12) ¼ -0.63, p ¼ 0.027 and r (11) ¼ -0.70,
p ¼ 0.016, respectively. Additionally, significant positive cor-
relations were found between class credits and PMS symp-
toms at month 5, r (11) ¼ 0.61, p ¼ 0.045.4. Discussion/conclusions
We report no group differences in PMS symptomatology be-
tween minority and non-minority collegiate women and this
finding is in contrast with our expectation and with the find-
ings of others [6]. Our cohort was comprised of collegiate
women and privileges afforded to a collegiate population may
have served to stratify our cohort and explain differences in
PMS symptomatology previously reported between minority
and non-minority groups in the general population [22].
Additionally, given our sample size limitation of this pilot
investigation, further larger-scale investigations should be
Table 2 eWithin group comparison of PMS symptoms at
baseline and following supplementation at month 5.
Race Baseline Month 5 Significance
(p value)
Non-minority
n ¼ 7
Mean (SD)
28.7 (±17.75) 9.0 (±10.46) 0.002
Minority
n ¼ 8
Mean (SD)
31.5 (±15.68) 12.5 (±11.55) 0.046
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we report a significant within-group reduction in PMS symp-
tomatology from baseline to month 5 following fish oil
supplementation. This significant reduction in PMS symp-
tomatology was found in both the minority and non-minority
cohorts with a large effect size. The large effect size we report
is highly significant from the clinical perspective with impli-
cations for PMS symptom management. Our finding of
reduced PMS symptomatology associated with fish oil sup-
plementation corroborates the evidence of reported reduction
in PMS symptoms associated with supplementation in the
general population [13,14]. Our evidence expands the litera-
ture by providing evidence of efficacy in both minority and
non-minority collegiate groups. Fish oil supplementationmay
offer an alternative in the management of PMS symptoms
compared to NSAIDs, which are associated with numerous
side effects including gastrointestinal and vascular distur-
bances [23].
PMS is a complex syndrome with multiple other variables
likely to impact onset and severity of symptoms. Given the
complex nature of PMS and based upon available evidence,
various lifestyle factors were considered with respect to PMS
symptomatology including stress, exercise habits, sleep
quality, caffeine intake and body mass index (BMI).
In the general population, more stress [17] and anxiety
sensitivity [16] have significant positive associations with
moderate to severe PMS symptom severity. In our investiga-
tion, factors including course credit load, work in addition to
school, marital status and living situation were evaluated as
potential factors likely to contribute to perceived stress level
in a population of collegiate women. Our finding of a signifi-
cant positive correlation between course credit load and PMS
symptom severity contributes to the evidence that the stress
of increased course credits may place collegiate women at
higher risk of suffering from PMS. Other factors including
work outside of school, marital status and living situation
were not found to be significantly associated with PMS
symptomatology. In this investigation the collegiate women
worked a minimal number of hours weekly and the influence
of hours worked on PMS symptomatology may be different in
the general population where women are likely to be working
significantly more hours weekly. Lastly, the marital status
and living arrangements were very similar across our colle-
giate cohort and were not significantly associated with PMS
symptomatology. In the general population marital status
and living situation should be evaluated regarding their rela-
tionship with PMS symptomatology.Regular physical activity is known for a multitude of
health benefits including stress reduction. From the perspec-
tive of the role of physical activity on PMS symptomatology,
Johnson et al. reported lower water retention and autonomic
reactions in women with higher aerobic activity [18]. In
contrast, Bianco et al. reported that sedentary lifestyle is
significantly associated with severe PMS symptomatology
[17]. Self-report of physical activity in this investigation was
not found to be significantly associated with PMS symptoms.
Our findings are in contrast with previous reports [17,18]. The
lack of association we report may in part be attributed to the
fact that the other investigations were in the general popu-
lation and that the cohort in our investigation were younger
and generally more active than the general population
where physical activity may make a more significant impact
on PMS symptomatology. Future investigations should
consider age variation with respect to physical activity and
PMS symptoms.
Scant research evidence is available with respect to sleep
quality and PMS symptom severity. A large investigation by
Cheng et al. reported that collegiate women with poorer sleep
quality had more severe symptoms of PMS [19]. Our finding of
no significant association between average nightly sleep
duration and PMS symptom severity is in contrast with the
previous report. In this investigation, self-report of sleep
duration was collected only once at the time of consent and
our evidence may be skewed without a formalized quantifi-
cation of sleep at regular monthly intervals.
Although higher caffeine intake has been reported to be
associated with higher PMS symptomatology [17,22], in this
investigation, caffeine intake was associated with lower PMS
symptomatology in minority collegiate women and therefore
beneficial in alleviating PMS symptoms. This relationship
between caffeine intake and reduced PMS symptomatology
warrants further larger-scale investigation.
The evidence is mixed regarding the association of BMI
with PMS symptomatology. Bianco et al. reported that women
with more severe PMS symptomatology had higher BMI [17].
In contrast, a recent investigation by Sahin et al. evaluated
BMI in association with PMS symptomatology in a cohort of
1008 collegiate women and reported that frequency of PMS
symptoms was significantly lower in students with over-
weight/obese BMI classifications [20]. The mean BMI in our
cohort was within the normal BMI classification and BMI
was not significantly associated with PMS symptomatology.
Collectively, our evidence combined the evidence of others
[17e20] is variable with respect to the influence of BMI on PMS
symptomatology highlighting need for further larger-scale
investigations.
These pilot results of a reduction in PMS symptoms in
both minority and non-minority women, and of no difference
between minority and non-minority groups, support a uni-
versal approach toward the treatment of PMS symptoms and
warrant larger-scale investigation. Omega-3 in the form of
fish oil provides a viable alternative toward alleviating PMS
symptomatology without associated risks that other phar-
macological interventions may impose. Overall, more
research should be conducted related to physical activity,
sleep duration, BMI and caffeine intake in lowering PMS
symptom severity. Research regarding stress reduction and
i n t e r n a t i o n a l j o u rn a l o f n u r s i n g s c i e n c e s 2 ( 2 0 1 5 ) 1 1 8e1 2 2122identification of stressors specific to women at different
stages of the menstrual lifespan is warranted. Educational
programming should be tailored to emphasize the health
benefits associated with regular fish intake and to educate
women regarding modifiable lifestyle factors that may reduce
PMS symptom severity.
Acknowledgments
This research was supported by the University of Connecticut
Rowe Scholars Program, Summer Undergraduate Research
Fund, and the Mr. Michael Alpert and Ariana Napier Honors
Enrichment Scholarship. The authors declare no conflict of
interest.r e f e r e n c e s
[1] Direkvand-Moghadam A, Sayehmiri K, Delpiseheh A,
Kaikhavandi S. Epidemiology of premenstrual syndrome
(PMS)-A systematic review and meta-analysis study. J Clin
Diagn Res 2014;8(2):106e9.
[2] Dickerson LM, Mazyck PJ, Hunter MH. Premenstrual
syndrome. Am Fam Physician 2003;67(8):1743e52.
[3] Halbriech U, Borenstien J, Pearlstein T, Kahn LS. The
prevalence, impairment, impact and burden of premenstrual
syndrome dysphoric disorder. Psychoneuroendocrinology
2003;3:1e23.
[4] Nisar N, Zehra N, Haider G, Munir AA, Sohoo NA. Frequency,
intensity and impact of premenstrual syndrome in medical
students. J Coll Physicians Surg Pak 2008;18(8):481e4.
[5] American Psychiatric Association. Diagnostic and Statistical
Manual of Mental Disorders. 5th ed. Arlington: American
Psychiatric Publishing; 2013.
[6] Harlow SD, Campbell OM. Epidemiology of menstrual
disorders in developing countries: a systematic review. BJOG
2004;111:6e16.
[7] Hamazaki T, Hirayama S. The effect of docosahexaenoic
acid-containing food administration on symptoms of
attention deficit/hyperactivity disorder e a placebo-
controlled double-blind study. Eur J Clin Nutr 2004;58:838.
[8] Ruxton C, Reed S, Simpson M, Millington K. The health
benefits of omega-3 polyunsaturated fatty acids: a review of
the evidence. J Hum Nutr Diet 2004;17:449e59. 20:275-285.
[9] Appleton K, Rogers P, Ness A. Updated systematic review and
meta-analysis of the effects of n-3 long-chainpolyunsaturated fatty acids on depressed mood. Am J Clin
Nutr 2010;91:757e70.
[10] Oz H, Chen T, Neuman M. Nutrition intervention: a strategy
against systemic inflammatory syndrome. J Parenter Enter
Nutr 2009;33:380e9.
[11] He K, Lui K, Daviglus ML, Jenny NS, Mayer-Davis E, Jiang R,
et al. Associations of dietary long-chain n-3 polyunsaturated
fatty acids and fish with biomarkers of inflammation and
endothelial activation. Am J Cardiol 2009;103:1238e43.
[12] Fontani G, Corradeschi F, Felici A, Alfatti F, Migliorini S,
Lodi L. Cognitive and physiological effects of omega-3
polyunsaturated fatty acid supplementation in healthy
subjects. Eur J Clin Invest 2004;35:691e9.
[13] Sampalis F, Bunea R, Pelland MF, Kowaski O, Duguet N,
Dupuis S. Evaluation of the effects of Neptune krill oil in the
management of premenstrual syndrome and dysmenorrhea.
Alt Med Rev 2003;8(2):171e9.
[14] Sohrabi N, Kashanian M, Ghafoori SS, Malakouti SK.
Evaluation of the effect of omega-3 fatty acids in the
treatment of premenstrual syndrome: a pilot trial.
Complement Ther Med 2013;21(3):141e6.
[15] Judge MP, Beck C. Handbook of Nutrition and Pregnancy
(Chapter 19). Totowa: Humana Press; 2012.
[16] Nillini YI, Rohan KJ, Mahon JN, Pineles SL, Zvolensky MJ. The
role of anxiety sensitivity in the experience of menstrual-
related symptoms reported via daily diary. Psychiatry Res
2013;210:564e9.
[17] Bianco V, Cestari AM, Casati D, Cipriani S, Radici G, Valente I.
Premenstrual syndrome and beyond: lifestyle, nutrition and
personal facts. Minerva Ginecol 2014;66(4):365e75.
[18] Johnson WG, Carr-Nangle RE, Bergeron KC. Macronutrient
intake, eating habits, and exercise as moderators of
menstrual distress in healthy women. Psychosom Med
1995;57(4):324e30.
[19] Cheng SH, Shih CC, Yang YK, Chen KT, Chang YH, Yang YC.
Factors associated with premenstrual syndrome- A survey of
new female university students. Kaohsiung J Med Sci
2013;29:100e5.
[20] Sahin S, Ozdemir K, Unsal A. Evaluation of premenstrual
syndrome and quality of life in university students. J Pak
Med Assoc 2014;64(8):915e22.
[21] Moos RH. The development of the menstrual distress
questionnaire. Psychosom Med 1968;30(6):853e67.
[22] Moos RH. Menstrual Distress Questionnaire Manual,
Instrument and Scoring Guide. 4th ed. Palo Alto: Healthcare
Evaluation; 2010.
[23] Coxib and Traditional NSAID Trialists’ (CNT) Collaboration.
Vascular and upper gastrointestinal effects of non steroid
anti-inflammatory drugs: meta-analyses of individual
participant data from randomized trials. Lancet
2013;382(9894):769e79.
